Moreover, HDAC6-specific inhibitors are being investigated as targeted therapeutics for peripheral neuropathy, in comparison to other HDAC inhibitors, especially in light of observations of HDAC6 regulation of neuronal microtubule stability (Rivieccio et al., 2009; d’Ydewalle et al., 2012; Simões-Pires et al., 2013; Wang et al., 2016). The gene discussed is HDAC6; the disease is peripheral neuropathy.